Cargando…
Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
A variety of pre-clinical and clinical data point toward high drug levels of retinoids being required to achieve optimal efficacy against neuroblastoma. The results of the Kohler trial reported in this issue demonstrate that low-dose 13-cis-RA does not have clinical efficacy against neuroblastoma in...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363592/ https://www.ncbi.nlm.nih.gov/pubmed/11027422 http://dx.doi.org/10.1054/bjoc.2000.1430 |